BeStock  
Stocks › Biotechnology › ALNY

Alnylam Pharmaceuticals ALNY

US equityMarket cap rank #931Biotechnology
$143.82 −$4.00 (-2.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $144.50 +0.47%
Open$148.35
Prev close$147.82
Day range$143.40 – $151.41
Volume2.33M
Market cap$19.26B
P/E (TTM)7.5
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$1.46B+16.7% YoY
Operating profit$345.80M-6.0% YoY
Net profit$2.17B+640.5% YoY
Diluted EPS$15.72+634.6% YoY
Free cash flow$271.15M-4.8% YoY
Operating cash flow$340.99M

Revenue, last 8 quarters

$593.2MDec '24$594.2MMar '25$773.7MJun '25$1.2BSep '25$1.1BDec '25$1.2BMar '26$1.3BJun '26$1.5BSep '26

Net profit, last 8 quarters

$-83.8MDec '24$-18.3MMar '25$-72.2MJun '25$292.7MSep '25$111.5MDec '25$206.0MMar '26$164.5MJun '26$2.2BSep '26

Diluted EPS by quarter

-0.65Dec '24-0.14Mar '25-0.55Jun '252.14Sep '250.82Dec '251.51Mar '261.21Jun '2615.72Sep '26

Free cash flow by quarter

$-103.8MDec '24$-129.3MMar '25$115.5MJun '25$284.7MSep '25$194.4MDec '25$48.7MMar '26$292.0MJun '26$271.2MSep '26

Annual revenue

$492.9MFY20$844.3MFY21$1.0BFY22$1.8BFY23$2.2BFY24$3.7BFY25

Profitability & balance sheet

Gross margin77.3%
Operating margin19.5%
Net margin52.8%
Return on equity138.1%
Return on assets41.2%
Return on invested capital86.2%
Current ratio2.48
Liabilities / assets54.9%
Cash & investments$3.59B
Total debt$1.22B
Net cash (debt)$2.37B
Free cash flow / sales16.1%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • AMVUTTRA$1.13B 77.5%
  • Royalty revenue$94.66M 6.5%
  • GIVLAARI$89.49M 6.1%
  • Net revenues from collaborations$71.48M 4.9%
  • OXLUMO$52.50M 3.6%
  • ONPATTRO$19.60M 1.3%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $1.46B $1.29B $1.17B $3.71B $1.10B
Total Operating Revenue $1.46B $1.29B $1.17B $3.71B $1.10B
Cost of Revenue $361.75M $298.45M $211.12M $681.87M $267.72M
Gross Profit $1.10B $992.50M $956.05M $3.03B $829.31M
Operating Expense $750.54M $761.06M $687.42M $2.53B $697.59M
Selling and Admin Expenses $342.00M $347.92M $322.55M $1.21B $325.37M
-General & Admin Expense $342.00M $347.92M $322.55M $1.21B $325.37M
Research & Development $408.54M $413.13M $364.87M $1.32B $372.22M
Operating Profit $345.80M $231.44M $268.64M $501.58M $131.72M
Net Non-Operating Interest Income (Expense) -$53.43M -$53.91M -$42.69M -$141.16M -$38.77M
Non-Operating Interest Income $30.94M $28.14M $26.60M $111.47M $26.63M
Non-Operating Interest Expense $84.37M $82.05M $69.29M $252.63M $65.40M
Other Income (Expense) $3.44M $273,000.00 -$4.30M -$37.27M -$6.69M
Special Income (Charges) $0.00 – – -$42.47M -$3.33M
Other Non-Operating Income (Expenses) $3.44M $273,000.00 -$4.30M $7.51M -$1.05M
Pretax Profit $295.81M $177.81M $221.65M $323.15M $86.26M
Tax -$1.87B $13.31M $15.66M $9.41M -$25.28M
Net Profit $2.17B $164.49M $205.99M $313.75M $111.54M
Profit from Continuing Operations $2.17B $164.49M $205.99M $313.75M $111.54M
Net Income to Parent Company $2.17B $164.49M $205.99M $313.75M $111.54M
Net Income to Common Stockholders $2.17B $164.49M $205.99M $313.75M $111.54M
Basic EPS $16.19 $1.23 $1.55 $2.39 $0.84
Diluted EPS $15.72 $1.21 $1.51 $2.33 $0.82
Gain on Sale of Security – – – -$2.31M $138.81M
-Less:Other Special Charges – – – $42.47M $3.33M

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $7.99B $5.56B $5.13B $4.97B $4.97B
Total Current Assets $5.11B $4.62B $4.22B $4.05B $4.05B
Cash and Cash Equivalents & Short-Term Investments $3.59B $3.31B $3.01B $2.91B $2.91B
-Cash and Cash Equivalents $1.75B $1.71B $1.71B $1.66B $1.66B
-Short Term Investments $1.83B $1.60B $1.30B $1.25B $1.25B
Receivables $1.08B $912.74M $883.96M $777.57M $777.57M
-Accounts Receivable $1.08B $912.74M $883.96M $777.57M $777.57M
Inventory $105.91M $97.11M $84.03M $82.72M $82.72M
Other Current Assets $334.60M $302.18M $242.10M $281.89M $281.89M
Total Non-Current Assets $2.88B $938.60M $910.24M $915.67M $915.67M
Net PPE $792.86M $737.50M $707.56M $708.06M $708.06M
-Gross PPE $792.86M $737.50M $707.56M $1.03B $1.03B
Non-Current Deferred Assets $2.01B $113.79M $116.96M $125.98M $125.98M
Other Non-Current Assets $82.48M $87.30M $85.72M $81.63M $81.63M
Total Liabilities $4.39B $4.20B $4.05B $4.18B $4.18B
Total Current Liabilities $2.06B $1.51B $1.35B $1.47B $1.47B
Payables $135.40M $108.02M $126.63M $115.72M $115.72M
-Accounts Payable $135.40M $108.02M $126.63M $115.72M $115.72M
Current Accrued Expenses $1.24B $1.10B $946.49M $823.00M $823.00M
Short-Term Debt and Capital Lease Obligation $407.61M $45.93M $45.66M $45.52M $45.52M
-Current Debt $361.53M – – – –
-Current Capital Lease Obligation $46.08M $45.93M $45.66M $45.52M $45.52M
Current Deferred Liabilities $11.67M $4.01M $3.21M $4.85M $4.85M
Other Current Liabilities $272.04M $258.57M $227.49M $220.07M $220.07M
Total Non-Current Liabilities $2.33B $2.69B $2.70B $2.71B $2.71B
Long Term Debt and Capital Lease Obligation $854.38M $1.22B $1.23B $1.23B $1.23B
-Long Term Debt $651.09M $1.01B $1.01B $1.01B $1.01B
-Long Term Capital Lease Obligation $203.29M $210.50M $218.03M $225.09M $225.09M
Other Non-Current Liabilities $1.47B $1.47B $1.48B $1.48B $1.48B
Total Equity $3.60B $1.35B $1.08B $789.18M $789.18M
Stockholders' Equity $3.60B $1.35B $1.08B $789.18M $789.18M
Capital Stock $1.34M $1.34M $1.33M $1.32M $1.32M
-Common Stock $1.34M $1.34M $1.33M $1.32M $1.32M
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $7.81B $7.72B $7.60B $7.51B $7.51B
Retained Earnings -$4.16B -$6.33B -$6.50B -$6.70B -$6.70B
Gains/Losses Not Affecting Retained Earnings -$44.66M -$32.14M -$24.89M -$20.10M -$20.10M
-Accumulated Depreciation – – – -$322.70M -$322.70M
Derivative Product Liabilities – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $340.99M $326.72M $70.50M $524.08M $217.73M
Net cash flow from continuing operations $340.99M $326.72M $70.50M $524.08M $217.73M
Net Income from Continuing Operations $2.17B $164.49M $205.99M $313.75M $111.54M
Depreciation & Depletion & Amortization $14.48M $13.90M $13.55M $55.66M $13.51M
Deferred Tax -$1.89B $2.66M $9.31M -$2.20M -$27.17M
Other Non-Cash Items $77.94M $87.32M $69.23M $251.11M $106.34M
Change in Working Capital -$103.15M -$28.27M -$297.73M -$444.78M -$18.98M
-Change in Receivables -$171.28M -$31.60M -$110.42M -$359.96M $184.25M
-Change in Inventory $913,000.00 $280,000.00 -$3.32M $8.47M -$13.86M
-Change in Prepaid Assets -$36.41M -$59.37M -$6.32M -$117.72M -$70.99M
-Change in Payables and Accrued Expense $95.96M $61.62M -$176.03M $75.07M -$120.68M
-Change In Other Working Capital $7.66M $802,000.00 -$1.63M -$50.64M $2.31M
Net cash flow from investing -$311.74M -$363.46M -$25.54M $436.33M -$37.17M
Net Cash Flow from Continuing Investing Activities -$311.74M -$363.46M -$25.54M $436.33M -$37.17M
Net PPE Purchase and Sale -$69.83M -$34.68M -$21.83M -$58.70M -$23.29M
Net Investment Purchase and Sale -$242.41M -$302.88M -$48.43M $497.18M -$13.87M
Net Other Investing Changes $500,000.00 -$25.90M $44.73M -$2.15M $0.00
Financing Cash Flow $18.35M $36.24M $15.71M -$305.19M -$8.86M
Net Cash Flow from Continuing Financing Activities $18.35M $36.24M $15.71M -$305.19M -$8.86M
Proceeds from Stock Option Exercised $15.47M $33.56M $13.16M $250.03M $41.70M
Net Other Financing Charges $12.75M $2.68M $2.56M -$10.69M -$8.27M
Ending Cash Balance $1.76B $1.71B $1.71B $1.66B $1.66B
Net Change in Cash $47.60M -$496,000.00 $60.68M $655.22M $171.71M
Beginning Cash Balance $1.71B $1.71B $1.66B $968.65M $1.49B
Effect of Exchange Rate Changes -$1.26M -$2.45M -$7.06M $34.94M -$5.70M
Free Cash Flow $271.15M $292.04M $48.67M $465.38M $194.44M
Gain/Loss from Continuing Operations – – – $2.31M -$39.15M
Net Issuance Payments Of Debt – – – -$544.53M -$42.29M

Discussion

No comments yet — be the first to weigh in on ALNY.

Sign in to join the discussion.

Scroll to Top